Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance

KRAS mutations drive resistance to targeted therapies, including EGFR inhibitors in colorectal cancer (CRC). Through genetic screens, we unexpectedly find that mutant HRAS, which is rarely found in CRC, is a stronger driver of resistance than mutant KRAS. This difference is ascribed to common codon...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Moiez, Kaltenbrun, Erin, Anderson, Gray R., Stephens, Sarah Jo, Arena, Sabrina, Bardelli, Alberto, Counter, Christopher M., Wood, Kris C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472712/
https://www.ncbi.nlm.nih.gov/pubmed/28593995
http://dx.doi.org/10.1038/ncomms15617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472712/
https://www.ncbi.nlm.nih.gov/pubmed/28593995
http://dx.doi.org/10.1038/ncomms15617

Ejemplares similares